Absci Corporation (NASDAQ:ABSI) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET
Company Participants
Alex Khan – VP of Finance and IR
Sean McClain – Founder and CEO
Zach Jonasson – CFO and CBO
Christian Stegmann – SVP of Drug Creation
Conference Call Participants
Arseniy Shabashvili – Guggenheim
Vikram Purohit – Morgan Stanley
Gil Blum – Needham & Company
Debanjana Chatterjee – Jones
Operator
Thank you for standing by and welcome to Absci’s Fourth Quarter and Full Year 2024 Business Update and Financial Operating Results Conference call. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, today’s program is being recorded. And now, I’d like to introduce your host for today’s program, Alex Khan, Vice President of Finance and Investor Relations.
Alex Khan
Thank you. Earlier today, Absci released financial and operating results for the quarter and year ended December 31, 2024. If you haven’t received this news release or if you’d like to be added to the company’s distribution list, please send an email to investors.absci.com. An archived webcast of this call will be available for replay at Absci’s Investor Relations website at investors.absci.com for at least 90 days after this call.
Joining me today are Sean McClain, Absci’s Founder and CEO, and Zach Jonasson, Chief Financial Officer and Chief Business Officer. Christian Stegmann, Absci’s SVP of Drug Creation, will also join for Q&A following prepared remarks.
Before we begin, I’d like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information
